| Ytd | -35.93% | |
| 1y | 4.90% |
| Open | 1.06 | Prev Close | 1.06 | Low | 1.05 | High | 1.09 | Mkt Cap | 266.75M |
| Vol | 1.13M | Avg Vol | 1.38M | EPS | -0.17 | P/E | -6.45 | Forward P/E | -3.66 |
| Beta | 1.28 | Short Ratio | 35.21 | Inst. Own | 50.56% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 1.19 | 200-d Avg | 1.52 | 1yr Est | 4.83 |
LCTX News
Lineage Cell Therapeutics NYSEAMERICAN: LCTX outlined progress across its cell-therapy pipeline duri
Lineage Cell Therapeutics, Inc. (LCTX) Q2 2026 Earnings Call Transcript
Lineage Cell (LCTX) came out with a quarterly loss of $0.03 per share in line with the Zacks Consens
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Q2 2026 Earnings Release.
Lineage Cell Therapeutics NYSEAMERICAN: LCTX used a conference call to outline its manufacturing str
Lineage Cell Therapeutics, Inc. (LCTX) Discusses COR1 Cell Transplant Program and Manufacturing Stra
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc
Lineage Cell Therapeutics NYSEAMERICAN: LCTX reported first-quarter 2026 results and used its earnin
Lineage Cell Therapeutics, Inc. (LCTX) Q1 2026 Earnings Call Transcript
Lineage Cell (LCTX) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Est
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc
AVAI, LCTX, OCGN, VRTX, and LGVN Advance Cell-Based and Gene-Therapy Approaches to Age-Related Disea
US stock futures up, Nasdaq 100 gains 100 pts. Service Properties Trust (SVC) drops 4% in pre-market
Defender Capital LLC. bought a new stake in shares of Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) used its quarterly conference call to highlight a long
Lineage Cell Therapeutics, Inc. (LCTX) Q4 2025 Earnings Call Transcript
Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterl
Companies Reporting Before The Bell • Takeda Pharmaceutical (NYSE:TAK) is likely to report earnings